Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures

European Journal of Clinical Investigation

Volumn 38, Issue 6, 2008, Pages 404-409

  Hsu, P I ^a,b   Wu, D C ^c   Chen, A ^d   Peng, N J ^a,b   Tseng, H H ^a,b   Tsay, F W ^a,b   Lo, G H ^a,b   Lu, C Y ^c,e   Yu, F J ^c   Lai, K H ^a,b  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^e Pingtung Hospital   (Taiwan)

Author keywords

Helicobacter pylori; Rescue therapy; Third line; Treatment

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; RABEPRAZOLE; TETRACYCLINE;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; ERADICATION THERAPY; FEMALE; FOLLOW UP; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; MALE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; TASTE DISORDER; TREATMENT DURATION; TREATMENT FAILURE; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; ORGANOMETALLIC COMPOUNDS; PATIENT SELECTION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 44049094179     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2008.01951.x     Document Type: Article

References (35)

1. Hsu PI, Lai KH, Lin CK, Chen WC, Yu HC, Cheng JS et al. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol 2005 100 : 2378 92.
2. Hsu PI, Lai KH, Wu CJ, Tseng HH, Tsay FW Peng NJ et al. High-dose versus low-dose esomeprazole-based triple therapy for Helicobacter pylori infection. Eur J Clin Invest 2007 37 : 724 30.
3. Gisbert JP, Khorrami S, Calvet X, Pajares JM. Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2004 16 : 89 99.
4. Wong WM, Gu Q, Chu KM, Yee YK, Fung FM, Tong TS et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006 23 : 421 7.
5. Gisbert JP, Pajares JM. Review article: Helicobacter pylori 'rescue' regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002 16 : 1047 57.
6. Wu DC, Hsu PI, Chen A, Lai KH, Tsay FW, Wu CJ et al. Randomized comparison of two rescue therapies for Helicobacter pylori infection. Eur J Clin Invest 2006 36 : 803 9.
7. McLoughlin RM, O'Morain CA, O'Connor HJ. Eradication of Helicobacter pylori: recent advances in treatment. Fundam Clin Pharmacol 2005 19 : 421 7.
8. Perri F, Festa V, Clemente R, Villani MR, Quitadamo M, Caruso N et al. Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001 96 : 58 62.
9. Wong WM, Gu Q, Lam SK, Fung FM, Lai KC, Hu WH et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003 17 : 553 60.
10. Treiber G, Ammon S, Malfertheiner P, Klotz U. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter 2002 7 : 225 31.
11. Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003 17 : 1333 43.
12. Gisbert JP, Gisbert JL, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares JM. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther 2008 27 : 346 54.
13. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 56 : 772 81.
14. Zullo A, Hassan C, Campo SM, Lorenzetti R, Febbraro I, De Matthaeis M et al. A triple therapy regimen after failed Helicobacter pylori treatments. Aliment Pharmacol Ther 2001 15 : 1193 7.
15. Kita T, Sakaeda T, Aoyama N, Sakai T, Kawahara Y, Kasuga M, Okumura K Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations. Biol Pharm Bull 2002 25 : 923 7.
16. Shirai N, Sugimoto M, Kodaira C, Nishino M, Ikuma M, Kajimura M et al. Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur J Clin Pharmacol 2007 63 : 743 9.
17. Megraud F. Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole shown in vitro. J Clin Gastroenterol 1995 20 (Suppl. 1 S24 7.
18. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006 101 : 1467 75.
19. Schwab M, Schaeffeler E, Klotz U, Treiber G. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther 2004 76 : 201 9.
20. Wu CJ, Hsu PI, Lo GH, Lo CC, Lin CK, Shie CB et al. Comparison of cetraxate-based and pantoprazole-based triple therapies in the treatment of Helicobacter pylori infection. J Chin Med Assoc 2004 67 : 161 7.
21. Hsu PI, Lai KH, Tseng HH, Lo GH, Lo CC, Lin CK et al. Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. Aliment Pharmacol Ther 2001 15 : 195 201.
22. Lo CC, Lai KH, Peng NJ, Lo GH, Tseng HH, Lin CK et al. Polymerase chain reaction: a sensitive method for detecting Helicobacter pylori infection in bleeding peptic ulcers. World J Gastroenterol 2005 11 (25) : 3909 14.
23. Hsu PI, Lai KH, Tseng HH, Liu YC, Yen MY, Lin CK et al. Correlation of serum immunoglobulin G Helicobacter pylori antibody titers with histologic and endoscopic findings in patients with dyspepsia. J Clin Gastroenterol 1997 25 : 587 91.
24. Hsu PI, Lai KH, Chien EJ, Lin CK, Lo GH, Jou HS et al. Impact of bacterial eradication on the cell proliferation and p53 protein accumulation in Helicobacter pylori-associated gastritis. Anticancer Res 2000 20 : 1221 8.
25. Peng NJ, Lai KH, Liu RS, Lee SC, Tsay DG, Lo CC et al. Endoscopic 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Dig Liver Dis 2003 35 : 73 7.
26. Peng NJ, Lai KH, Liu RS, Lee SC, Tsay DG, Lo CC et al. Clinical significance of oral urease in diagnosis of Helicobacter pylori infection by [13C]urea breath test. Dig Dis Sci 2001 46 : 1772 8.
27. Hsu PI, Hwang IR, Cittelly D, Lai KH, El-Zimaity HM, Gutierrez O et al. Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island. Am J Gastroenterol 2002 97 : 2231 8.
28. Tanigawara Y, Aoyama N, Kita T, Shirakawa K, Komada F, Kasuga M et al. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 1999 66 : 528 34.
29. Gatta L, Zullo A, Perna F, Ricci C, De Francesco V, Tampieri A et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005 22 : 45 9.
30. Gisbert JP, Castro-Fernández M, Bermejo F, Pérez-Aisa A, Ducons J, Fernández-Bermejo M et al. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol 2006 101 : 243 7.
31. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004 5 : 181 202.
32. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 2006 44 : 297 302.
33. Aoyama N, Tanigawara Y, Kita T, Sakai T, Shirakawa K, Shirasaka D et al. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. J Gastroenterol 1999 34 (Suppl. 1 80 3.
34. Piccolomini R, Bonaventura GD, Catamo G, Carbone F, Neri M. Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents. J Clin Microbiol 1997 35 : 1842 6.
35. Best LM, Haldane DJM, Keelan M. Taylor DE, Thomson ABR, Loo V et al. Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. Antimicrobiol Agents Chemother 2003 47 : 3138 44.